Invex Therapeutics Ltd (ASX:IXC) Share Price and News

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.

Expand Company Description

Market Cap (10-Oct) $6,087,458 (1,207th)	Close (30-Jun) $0.200 0 (0%)	Volume (30-Jun) 1,808,064	Shortsold (19-Jul) 2,718 (0.00%) (565th)
52w High $0.340	52w Low $0.060	P/E -	EPS -0.02

	Subject
	IXC IXC Ann: Phase III Clinical Trial Update and New IIH Market Analysis
	1 (current) 2 3
	IXC IXC Ann: Invex Granted European Orphan Drug Designation for TBI
	IXC IXC Ann: Invex Receives Regulatory Approval for IIH EVOLVE in France
	IXC IXC Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	IXC IXC Ann: Israel Ministry of Health Approval for IIH EVOLVE
	IXC IXC Ann: March Appendix 4C and Investor Conference Call Details
	IXC IXC Ann: Notification of cessation of securities - IXC
	IXC IXC Ann: German Approval for IIH EVOLVE Phase 3 Clinical Trial
	IXC IXC Ann: Publication of Invex IIH Phase II Pressure Trial Results
	IXC IXC Ann: Half Year Accounts
	IXC IXC Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	IXC IXC Ann: Notification of cessation of securities - IXC
	IXC IXC Ann: Notice of Quarterly Investor Call
	IXC IXC Ann: First US Clinical Site Activated in IIH EVOLVE Phase III
	IXC IXC Ann: Invex Receives Approval for Paediatric Plan from the EMA
	IXC IXC Ann: Update - Notification regarding unquoted securities - IXC
	IXC IXC Ann: Change of Director's Interest Notice x 4
	IXC IXC Ann: Notification regarding unquoted securities - IXC
	IXC IXC Ann: Invex to Present at the MST Financial Biotech Forum
	IXC IXC Ann: MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ
	IXC IXC Ann: Investor Presentation
	IXC IXC Ann: Results of Meeting
	IXC IXC Ann: AGM Presentation
	IXC IXC Ann: AGM Chairmans Address
	IXC IXC Ann: First Patient Randomised in IIH EVOLVE Phase III Trial
	IXC IXC Ann: Invex Receives $0.46 Million R&D Tax Rebate
	IXC IXC Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	IXC IXC Ann: Upcoming Presentation at Argonaut Biotech Briefing
	IXC IXC Ann: September Appendix 4C and Investor Conference Call Details
	IXC IXC Ann: First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial
	IXC IXC Ann: First Australian Site Activated in IIH EVOLVE Phase 3
	IXC IXC Ann: Notice of Annual General Meeting/Proxy Form
	IXC IXC Ann: Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
	IXC IXC Ann: Date of AGM and Director Nominations
	IXC IXC Ann: Invex to Present at Virtual ASX Small and Mid-Cap Conference
	IXC IXC Ann: Appendix 4G
	IXC IXC Ann: Corporate Governance Statement
	IXC IXC Ann: 4E and Annual Report to shareholders
	IXC IXC Ann: Invex receives IND approval
	IXC IXC Ann: Trading Halt
	IXC IXC Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	IXC IXC Ann: HREC and TGA Approval to Commence Phase 3 in Australia
	IXC IXC Ann: Appendix 4C and Investor Conference Call Details
	IXC IXC Ann: Invex Receives UK Approval to Commence Phase III Trial
	IXC IXC Ann: Upcoming Presentations to the 15th EUNOS Meeting
	IXC IXC Ann: Invex to Present at Aerospace Medical Association Meeting
	IXC IXC Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	IXC IXC Ann: March Appendix 4C and Investor Conference Call Details
	IXC IXC Ann: Executive Director Agreement
	IXC IXC Ann: Invex to Present at Upcoming Tech Biotech Broker Briefing

Similar Companies

Cann Group

CAN

Creso Pharma

CPH

Ecofibre

EOF

Incannex Healthcare

IHL

Medical Developments International

MVP

Mayne Pharma Group

MYX

Neuren Pharmaceuticals

NEU

Probiotec

PBP

Recce Pharmaceuticals Ltd

RCE

Starpharma Holdings

SPL

End of Day Prices

Date	Close	Volume	Change
10-Oct	$0.09	117,073	+0.00 (6.17%)
09-Oct	$0.08	80,085	0.00 (2.41%)
08-Oct	$0.08	0	0.00 (0.00%)
07-Oct	$0.08	75,208	+0.00 (1.22%)
04-Oct	$0.08	2,177	0.00 (0.00%)
03-Oct	$0.08	273,133	+0.00 (2.50%)
02-Oct	$0.08	65,000	+0.01 (6.67%)
01-Oct	$0.08	8,000	0.00 (0.00%)
30-Sep	$0.08	12,195	+0.00 (5.63%)
11-Sep	$0.07	0	0.00 (0.00%)
10-Sep	$0.07	2,777	+0.00 (1.43%)
09-Sep	$0.07	5,405	0.00 (1.41%)
06-Sep	$0.07	0	0.00 (0.00%)
05-Sep	$0.07	1,050	+0.00 (1.43%)
04-Sep	$0.07	0	0.00 (0.00%)
7 up, 2 down, and 6 flat days

High $0.21	Low $0.19	Trades 113	Turnover $359,726	Volume 1,808,064
30 June 2023 at 4:10pm

High $0.21	Low $0.19	Trades 113	Turnover $359,726	Volume 1,808,064
30 June 2023 at 4:10pm

Invex Therapeutics Ltd Health Care

$0.200 0.005 (2.56%)

$0.200 0.005 (2.56%)

Followers

Prices

Announcements

Similar Companies

End of Day Prices